Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

E2F1 inhibition mediates cell death of metastatic melanoma.

Rouaud F, Hamouda-Tekaya N, Cerezo M, Abbe P, Zangari J, Hofman V, Ohanna M, Mograbi B, El-Hachem N, Benfodda Z, Lebeau A, Tulic MK, Hofman P, Bertolotto C, Passeron T, Annicotte JS, Ballotti R, Rocchi S.

Cell Death Dis. 2018 May 1;9(5):527. doi: 10.1038/s41419-018-0566-1.

2.

Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.

Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Beranger G, Mograbi B, Rocchi S, Yvan-Charvet L, Ballotti R, Bertolotto C.

Genes Dev. 2018 Mar 1;32(5-6):448-461. doi: 10.1101/gad.305854.117. Epub 2018 Mar 22.

PMID:
29567766
3.

Uncovering and deciphering the pro-invasive role of HACE1 in melanoma cells.

El-Hachem N, Habel N, Naiken T, Bzioueche H, Cheli Y, Beranger GE, Jaune E, Rouaud F, Nottet N, Reinier F, Gaudel C, Colosetti P, Bertolotto C, Ballotti R.

Cell Death Differ. 2018 Mar 7. doi: 10.1038/s41418-018-0090-y. [Epub ahead of print]

PMID:
29515254
4.

Deregulated MITF sumoylation: A route to melanoma.

Ballotti R, Bertolotto C.

Mol Cell Oncol. 2017 May 26;4(4):e1331154. doi: 10.1080/23723556.2017.1331154. eCollection 2017.

5.

Pathways from senescence to melanoma: focus on MITF sumoylation.

Leclerc J, Ballotti R, Bertolotto C.

Oncogene. 2017 Nov 30;36(48):6659-6667. doi: 10.1038/onc.2017.292. Epub 2017 Aug 21. Review.

PMID:
28825724
6.

Focus on cutaneous and uveal melanoma specificities.

Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C.

Genes Dev. 2017 Apr 15;31(8):724-743. doi: 10.1101/gad.296962.117. Review.

7.

Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit.

Montaudié H, Cerezo M, Bahadoran P, Roger C, Passeron T, Machet L, Arnault JP, Verneuil L, Maubec E, Aubin F, Granel F, Giacchero D, Hofman V, Lacour JP, Maryline A, Ballotti R, Rocchi S.

Pigment Cell Melanoma Res. 2017 May;30(3):378-380. doi: 10.1111/pcmr.12576. Epub 2017 Apr 22. No abstract available.

PMID:
28122176
8.

FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells.

Bourseguin J, Bonet C, Renaud E, Pandiani C, Boncompagni M, Giuliano S, Pawlikowska P, Karmous-Benailly H, Ballotti R, Rosselli F, Bertolotto C.

Sci Rep. 2016 Nov 9;6:36539. doi: 10.1038/srep36539.

9.

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.

Richard G, Dalle S, Monet MA, Ligier M, Boespflug A, Pommier RM, de la Fouchardière A, Perier-Muzet M, Depaepe L, Barnault R, Tondeur G, Ansieau S, Thomas E, Bertolotto C, Ballotti R, Mourah S, Battistella M, Lebbé C, Thomas L, Puisieux A, Caramel J.

EMBO Mol Med. 2016 Oct 4;8(10):1143-1161. doi: 10.15252/emmm.201505971. Print 2016 Oct.

10.

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.

Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, Passeron T, Hofman V, Mograbi B, Dabert-Gay AS, Debayle D, Alcor D, Rabhi N, Annicotte JS, Héliot L, Gonzalez-Pisfil M, Robert C, Moréra S, Vigouroux A, Gual P, Ali MMU, Bertolotto C, Hofman P, Ballotti R, Benhida R, Rocchi S.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.007. Epub 2016 Jul 11. No abstract available.

11.

Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance.

Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, Passeron T, Hofman V, Mograbi B, Dabert-Gay AS, Debayle D, Alcor D, Rabhi N, Annicotte JS, Héliot L, Gonzalez-Pisfil M, Robert C, Moréra S, Vigouroux A, Gual P, Ali MMU, Bertolotto C, Hofman P, Ballotti R, Benhida R, Rocchi S.

Cancer Cell. 2016 Jun 13;29(6):805-819. doi: 10.1016/j.ccell.2016.04.013. Epub 2016 May 26. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

12.

NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.

De Donatis GM, Le Pape E, Pierron A, Cheli Y, Hofman V, Hofman P, Allegra M, Zahaf K, Bahadoran P, Rocchi S, Bertolotto C, Ballotti R, Passeron T.

Oncogene. 2016 May;35(21):2813. doi: 10.1038/onc.2015.468. No abstract available.

PMID:
27225420
13.

High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness.

Long E, Ilie M, Bence C, Butori C, Selva E, Lalvée S, Bonnetaud C, Poissonnet G, Lacour JP, Bahadoran P, Brest P, Gilson E, Ballotti R, Hofman V, Hofman P.

Cancer Med. 2016 Jun;5(6):1022-30. doi: 10.1002/cam4.661. Epub 2016 Mar 6.

14.

Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P; French Familial Melanoma Study Group, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B.

Nature. 2016 Mar 3;531(7592):126. doi: 10.1038/nature16158. Epub 2015 Dec 2. No abstract available.

PMID:
26633630
15.

NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.

De Donatis GM, Le Pape E, Pierron A, Cheli Y, Hofman V, Hofman P, Allegra M, Zahaf K, Bahadoran P, Rocchi S, Bertolotto C, Ballotti R, Passeron T.

Oncogene. 2016 May;35(21):2735-45. doi: 10.1038/onc.2015.331. Epub 2015 Sep 14. Erratum in: Oncogene. 2016 May;35(21):2813.

PMID:
26364600
16.

Transcriptional Analysis of Vitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target for Repigmenting Vitiligo Patients.

Regazzetti C, Joly F, Marty C, Rivier M, Mehul B, Reiniche P, Mounier C, Rival Y, Piwnica D, Cavalié M, Chignon-Sicard B, Ballotti R, Voegel J, Passeron T.

J Invest Dermatol. 2015 Dec;135(12):3105-3114. doi: 10.1038/jid.2015.335. Epub 2015 Aug 31.

17.

Endothelial Cells Promote Pigmentation through Endothelin Receptor B Activation.

Regazzetti C, De Donatis GM, Ghorbel HH, Cardot-Leccia N, Ambrosetti D, Bahadoran P, Chignon-Sicard B, Lacour JP, Ballotti R, Mahns A, Passeron T.

J Invest Dermatol. 2015 Dec;135(12):3096-3104. doi: 10.1038/jid.2015.332. Epub 2015 Aug 26.

18.

Identification of melanoma initiating cells: does CD271 have a future?

Ballotti R.

Future Oncol. 2015;11(11):1587-90. doi: 10.2217/fon.15.24. No abstract available.

19.

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.

Stark MS, Bonazzi VF, Boyle GM, Palmer JM, Symmons J, Lanagan CM, Schmidt CW, Herington AC, Ballotti R, Pollock PM, Hayward NK.

Oncotarget. 2015 Jul 10;6(19):17753-63.

20.

NF1 loss induces senescence during human melanocyte differentiation in an iPSC-based model.

Larribere L, Wu H, Novak D, Galach M, Bernhardt M, Orouji E, Weina K, Knappe N, Sachpekidis C, Umansky L, Beckhove P, Umansky V, De Schepper S, Kaufmann D, Ballotti R, Bertolotto C, Utikal J.

Pigment Cell Melanoma Res. 2015 Jul;28(4):407-16. doi: 10.1111/pcmr.12369. Epub 2015 Apr 22.

PMID:
25824590
21.

Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.

Ilie M, Long-Mira E, Funck-Brentano E, Lassalle S, Butori C, Lespinet-Fabre V, Bordone O, Gay A, Zahaf K, Poissonnet G, Lacour JP, Bahadoran P, Ballotti R, Gros A, Dutriaux C, Saiag P, Merlio JP, Vergier B, Emile JF, Hofman V, Hofman P.

J Am Acad Dermatol. 2015 May;72(5):786-93. doi: 10.1016/j.jaad.2015.01.012. Epub 2015 Feb 7.

PMID:
25659223
22.

Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib.

Lehraiki A, Cerezo M, Rouaud F, Abbe P, Allegra M, Kluza J, Marchetti P, Imbert V, Cheli Y, Bertolotto C, Ballotti R, Rocchi S.

Cell Discov. 2015 Oct 27;1:15030. doi: 10.1038/celldisc.2015.30. eCollection 2015.

23.

CD271 is an imperfect marker for melanoma initiating cells.

Cheli Y, Bonnazi VF, Jacquel A, Allegra M, De Donatis GM, Bahadoran P, Bertolotto C, Ballotti R.

Oncotarget. 2014 Jul 30;5(14):5272-83.

24.

Is it time to test biguanide metformin in the treatment of melanoma?

Cerezo M, Tomic T, Ballotti R, Rocchi S.

Pigment Cell Melanoma Res. 2015 Jan;28(1):8-20. doi: 10.1111/pcmr.12267. Epub 2014 Jun 26. Review.

PMID:
24862830
25.

Inhibition of melanogenesis by the antidiabetic metformin.

Lehraiki A, Abbe P, Cerezo M, Rouaud F, Regazzetti C, Chignon-Sicard B, Passeron T, Bertolotto C, Ballotti R, Rocchi S.

J Invest Dermatol. 2014 Oct;134(10):2589-2597. doi: 10.1038/jid.2014.202. Epub 2014 Apr 22.

26.

SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells.

Ohanna M, Bonet C, Bille K, Allegra M, Davidson I, Bahadoran P, Lacour JP, Ballotti R, Bertolotto C.

Oncotarget. 2014 Apr 30;5(8):2085-95.

27.

Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.

Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, Bille K, Bahadoran P, Giacchero D, Lacour JP, Boyle GM, Hayward NF, Bertolotto C, Ballotti R.

Oncotarget. 2013 Dec;4(12):2212-24.

28.

A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.

Allegra M, Giacchero D, Segalen C, Dumaz N, Butori C, Hofman V, Hofman P, Lacour JP, Bertolotto C, Bahadoran P, Ballotti R.

J Invest Dermatol. 2014 May;134(5):1473-1476. doi: 10.1038/jid.2013.525. Epub 2013 Dec 6. No abstract available.

29.

PGJ2 restores RA sensitivity in melanoma cells by decreasing PRAME and EZH2.

Pierron A, Le Pape E, Montaudié H, Castela E, De Donatis GM, Allegra M, Bertolotto C, Rocchi S, Cheli Y, Ballotti R, Passeron T.

J Dermatol Sci. 2014 Mar;73(3):258-61. doi: 10.1016/j.jdermsci.2013.11.003. Epub 2013 Nov 11. No abstract available.

PMID:
24289988
30.

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.

Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M, Rocchi S, Bahadoran P, McCalmont TH, LeBoit PE, Burton EA, Bollag G, Ballotti R, Bastian BC.

Pigment Cell Melanoma Res. 2013 Nov;26(6):845-51. doi: 10.1111/pcmr.12148. Epub 2013 Aug 19.

31.

Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.

Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P, Bertolotto C, Tartare-Deckert S, Ballotti R, Rocchi S.

Mol Cancer Ther. 2013 Aug;12(8):1605-15. doi: 10.1158/1535-7163.MCT-12-1226-T. Epub 2013 Jun 5.

32.

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D, Passeron T, Lacour JP, Ballotti R.

J Clin Oncol. 2013 Jul 1;31(19):e324-6. doi: 10.1200/JCO.2012.46.1061. Epub 2013 May 28. No abstract available.

PMID:
23715574
33.

Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California.

Lo RS, Ribas A, Long GV, Ballotti R, Berger M, Willy H, Gibney GT, Bosenberg M, Bernstein E, Villanueva J, Smalley KS.

Pigment Cell Melanoma Res. 2013 Jul;26(4):E1-7. doi: 10.1111/pcmr.12103. Epub 2013 May 13. No abstract available.

PMID:
23551976
34.

Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.

Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G.

Haematologica. 2013 Feb;98(2):e20-2. doi: 10.3324/haematol.2012.082404. Epub 2013 Jan 8. No abstract available.

35.

The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.

Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S.

PLoS One. 2012;7(7):e40378. doi: 10.1371/journal.pone.0040378. Epub 2012 Jul 20.

36.

Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.

Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, Bahadoran P, Rocchi S, Ballotti R, Bertolotto C.

J Biol Chem. 2012 Aug 24;287(35):29887-98. doi: 10.1074/jbc.M112.371682. Epub 2012 Jul 5.

37.

Cystinosin is a melanosomal protein that regulates melanin synthesis.

Chiaverini C, Sillard L, Flori E, Ito S, Briganti S, Wakamatsu K, Fontas E, Berard E, Cailliez M, Cochat P, Foulard M, Guest G, Niaudet P, Picardo M, Bernard FX, Antignac C, Ortonne JP, Ballotti R.

FASEB J. 2012 Sep;26(9):3779-89. doi: 10.1096/fj.11-201376. Epub 2012 May 30.

PMID:
22649030
38.

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Passeron T, Lacour JP, Allegra M, Ségalen C, Deville A, Thyss A, Giacchero D, Ortonne JP, Bertolotto C, Ballotti R, Bahadoran P.

Exp Dermatol. 2011 Dec;20(12):1030-2. doi: 10.1111/j.1600-0625.2011.01385.x.

PMID:
22092579
39.

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P; French Familial Melanoma Study Group, Aubin F, Bachollet B, Becuwe C, Berthet P, Bignon YJ, Bonadona V, Bonafe JL, Bonnet-Dupeyron MN, Cambazard F, Chevrant-Breton J, Coupier I, Dalac S, Demange L, d'Incan M, Dugast C, Faivre L, Vincent-Fétita L, Gauthier-Villars M, Gilbert B, Grange F, Grob JJ, Humbert P, Janin N, Joly P, Kerob D, Lasset C, Leroux D, Levang J, Limacher JM, Livideanu C, Longy M, Lortholary A, Stoppa-Lyonnet D, Mansard S, Mansuy L, Marrou K, Matéus C, Maugard C, Meyer N, Nogues C, Souteyrand P, Venat-Bouvet L, Zattara H, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B.

Nature. 2011 Oct 19;480(7375):94-8. doi: 10.1038/nature10539. Erratum in: Nature. 2016 Mar 3;531(7592):126.

PMID:
22012259
40.

Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells.

Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, Ballotti R.

Oncogene. 2012 May 10;31(19):2461-70. doi: 10.1038/onc.2011.425. Epub 2011 Sep 26.

PMID:
21996743
41.

In vivo reflectance confocal microscopy of the skin: a noninvasive means of assessing body cystine accumulation in infantile cystinosis.

Chiavérini C, Kang HY, Sillard L, Berard E, Niaudet P, Guest G, Cailliez M, Bahadoran P, Lacour JP, Ballotti R, Ortonne JP.

J Am Acad Dermatol. 2013 Apr;68(4):e111-e116. doi: 10.1016/j.jaad.2011.08.010. Epub 2011 Oct 2.

PMID:
21963264
42.

Metformin inhibits melanoma development through autophagy and apoptosis mechanisms.

Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder JM, Tartare-Deckert S, Bahadoran P, Auberger P, Ballotti R, Rocchi S.

Cell Death Dis. 2011 Sep 1;2:e199. doi: 10.1038/cddis.2011.86.

43.

Biological and mathematical modeling of melanocyte development.

Luciani F, Champeval D, Herbette A, Denat L, Aylaj B, Martinozzi S, Ballotti R, Kemler R, Goding CR, De Vuyst F, Larue L, Delmas V.

Development. 2011 Sep;138(18):3943-54. doi: 10.1242/dev.067447.

44.

GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells.

Javelaud D, Alexaki VI, Pierrat MJ, Hoek KS, Dennler S, Van Kempen L, Bertolotto C, Ballotti R, Saule S, Delmas V, Mauviel A.

Pigment Cell Melanoma Res. 2011 Oct;24(5):932-43. doi: 10.1111/j.1755-148X.2011.00893.x. Epub 2011 Aug 18.

PMID:
21801332
45.

SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.

Fenouille N, Puissant A, Tichet M, Zimniak G, Abbe P, Mallavialle A, Rocchi S, Ortonne JP, Deckert M, Ballotti R, Tartare-Deckert S.

Oncogene. 2011 Dec 8;30(49):4887-900. doi: 10.1038/onc.2011.198. Epub 2011 Jun 20.

PMID:
21685937
46.

Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS).

Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, Bille K, Robert C, Bressac-de Paillerets B, Hofman P, Rocchi S, Peyron JF, Lacour JP, Ballotti R, Bertolotto C.

Genes Dev. 2011 Jun 15;25(12):1245-61. doi: 10.1101/gad.625811. Epub 2011 Jun 6.

47.

BRCA1 is a new MITF target gene.

Beuret L, Ohanna M, Strub T, Allegra M, Davidson I, Bertolotto C, Ballotti R.

Pigment Cell Melanoma Res. 2011 Aug;24(4):725-7. doi: 10.1111/j.1755-148X.2011.00862.x. Epub 2011 May 13. No abstract available.

PMID:
21501420
48.

Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.

Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, Hofman P, Bahadoran P, Bertolotto C, Ballotti R.

Oncogene. 2011 May 19;30(20):2307-18. doi: 10.1038/onc.2010.598. Epub 2011 Jan 31. Erratum in: Oncogene. 2011 May 19;30(20):2390. Guiliano, S [corrected to Giuliano, S].

PMID:
21278797
49.

Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma.

Strub T, Giuliano S, Ye T, Bonet C, Keime C, Kobi D, Le Gras S, Cormont M, Ballotti R, Bertolotto C, Davidson I.

Oncogene. 2011 May 19;30(20):2319-32. doi: 10.1038/onc.2010.612. Epub 2011 Jan 24.

PMID:
21258399
50.

Advances in melanoma senescence and potential clinical application.

Giuliano S, Ohanna M, Ballotti R, Bertolotto C.

Pigment Cell Melanoma Res. 2011 Apr;24(2):295-308. doi: 10.1111/j.1755-148X.2010.00820.x. Epub 2011 Jan 11. Review.

PMID:
21143770

Supplemental Content

Loading ...
Support Center